BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 ...

Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following ...

Q4 2025 earnings call: record $589M revenue, 2026 guidance, FIRDAPSE/AGAMREE growth drivers, and key risks—read now.

Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year ...

Revenue collection has also weakened. The tax-to-GDP ratio has fallen to 6.8%, one of the lowest in South Asia.

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Mahenge is one of the more advanced large-flake graphite projects globally. It has a resource estimate of 213Mt at 7.8% TGC, ...

Amid growing protectionism and geopolitical uncertainty, China took over from the United States to become Germany's largest trading partner in 2025, according to Germany's Federal Statistical Office, ...

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained ...

Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 mil ...

Interested in starting a business, learning about artificial intelligence or exploring a new hobby? There's a class for that.